GHRP-6
GHRP-6 is a synthetic hexapeptide growth-hormone secretagogue that acts at the ghrelin receptor.
The short version
- Why people discuss it
- Discussed for appetite stimulation, weight gain, growth-hormone signaling and recovery. Community interest does not establish benefit or a suitable treatment.
- What it is
- GHRP-6 is a synthetic hexapeptide growth-hormone secretagogue that acts at the ghrelin receptor.
- Biggest caution
- Acute growth-hormone or appetite responses do not establish muscle gain, fat loss or a safe repeat-use regimen. Product identity and long-term human safety remain unresolved.
- Stack context
- Related profiles reflect adjacent community topics or biological context. They do not establish combination benefit, compatibility or a validated regimen.
Dose and frequency reference
Reference only — not a recommendation. Amounts describe source-specific community examples, selected study regimens or the named product label. They do not establish safety, effectiveness, product identity, or a suitable dose for any person. Never convert mg, mcg, or IU into syringe “units” without the exact product concentration.
Source agreement describes reported practice, not clinical validation.
Subcutaneous injection
Community reference · Not clinical guidance- Amount
- 100–150 mcg per administration
- Frequency
- 2–3 times daily
- Duration / phase
- 8–12 weeks
Lower overlapping community range. PeptideDosages escalates to 300 mcg three times daily; that is a higher reported variant rather than agreement on a typical amount. Reference only; this does not establish safety, effectiveness or individual suitability.
Community source · reviewed 2026-09-27Compare reported schedules
Saved source material reviewed 2026-09-27. Multiple pages from one publisher count as one source family; agreement does not establish what most people use. SC means subcutaneous; IM intramuscular; IP intraperitoneal.
- PeptideDosages — saved source reviewed September 27, 2026
100→300 mcg SC per injection three times/day, 8–12 weeks.
- Peptidepedia — saved source reviewed September 27, 2026
100–150 mcg typically 2–3 times/day, 8–16 weeks; advanced 150 mcg three times/day.
Evidence & sources · Community source profile
AxonRep synthesizes community discussion signals from its internal research corpus. Individual creator sources remain attributed to the synthesis; public reference sites used in the latest comparison are linked separately. The synthesis is not clinical evidence.
- AxonRep community research synthesisAxonRep synthesis · Checked 2026-09-12
- PeptideDosages — saved source reviewed September 27, 2026Community reference · Checked 2026-09-27
- Peptidepedia — saved source reviewed September 27, 2026Community reference · Checked 2026-09-27